CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 101 enrolled
Drug / intervention
Varenicline +1 moredrug
Likely dose
Varenicline 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00789074
NCT00789074Phase 3Completed

Effects of an Extended Period of Varenicline Use Prior to Quitting Smoking on Post-quitting Urges to Smoke

Queen Mary University of London·interventional·Posted Nov 11, 2008·Updated Dec 12, 2013

In Brief

A Phase 3 clinical trial evaluating Varenicline and Placebo for Tobacco Dependence and Smoking Cessation. Completed, enrolled 101 participants across 1 site.

Detailed Summary

Varenicline (Champix) is a relatively new medicine that is effective in helping people to quit smoking. It is normally started 1-week before stopping smoking and used for up to 12-24 weeks. We are trying to find out if using varenicline for an extended time (4-weeks) before stopping smoking is better than the standard 1-week of use prior to stopping. The study will recruit 100 smokers who want to stop. They will be randomly allocated to receive varenicline(4-weeks) or placebo (3-weeks followed by 1-week of active treatment as indicated by standard prescribing practice), followed by a 12-week open label treatment period where all participants will receive varenicline.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 11, 2008
Enrollment StartJul 1, 2009
Primary CompletionDec 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.6 years ago

Interventions

Vareniclinedrug

Varenicline 1mg twice daily

Placebodrug

Placebo 1mg BD